Biostar pharmaceuticals, inc. (BSPM)
CashFlow / Quarterly
Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES
Net loss

-125

-1,314

-1,014

3,388

-1,563

-6,902

-620

-23,205

-1,254

-492

-160

2,656

239

1,645

306

592

386

-730

560

-6,742

-5,939

-9,482

2,167

833

4,463

4,152

2,723

Adjustments to reconcile net income to net cash provided by operating activities:
Accrued interest income

-

-

-

-

-

-

-

-

630

1

317

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred tax benefit

-

-

-

-

-

-

-

1,913

67

-169

-478

-3,828

285

-604

-137

447

302

-129

360

-330

109

-2,331

516

-

-

-

-

Depreciation and amortization

300

281

297

229

400

195

316

1,314

27

490

487

617

877

855

736

759

803

764

458

459

455

456

456

488

143

145

107

Recognition of deferred research and development expenses

-

-

-

-

-

-

-

3,006

-7

3

1,018

1,383

-1

689

694

816

811

805

796

-

-

-

-

-

-

-

-

Impairment loss on loan receivable

-

-

-

-

-

-

-

-

-

-

-

-2,155

-1,690

1,576

2,269

-

-

-

-

-

-

-

-

-

-

-

-

Provision for doubtful accounts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Recognition of deferred research and development expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

791

-

-

-

-

Stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

66

1,755

99

99

143

607

0

6

28

722

28

43

-

-

-

-

Fair value adjustment on warrants

-

-

-

-

-

-

-

99

144

90

-9

236

-51

393

0

-

-

-

-

-

-

-

-

-

-

-

-

Fair value adjustment on warrants

12

259

16

-

2

16

28

-

-

-

-

-

-373

314

-314

-

312

1,208

-449

-

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Stock-based compensation and other non-cash expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

149

1,315

178

Accounts receivable

-69

-5,571

-1,238

-7,064

-107

-307

-1,190

-10,144

1,813

5,351

-2,468

-4,623

3,004

5,609

3,450

5,045

-513

-3,278

-5,457

-9,176

6,275

-3,011

-716

2,400

-464

3,973

-576

Inventories

-0

-0

-3

-269

124

33

56

-400

141

119

-280

-67

69

-63

-91

-383

-531

309

562

-143

143

-107

-428

-838

138

914

395

Deposits and other receivables

135

172

-155

176

0

0

0

1,927

-1,498

-730

-90

1,427

-755

479

-1,396

643

-131

-1,114

764

1,870

0

0

-0

-4

-1

62

-46

Accounts payable and accrued expenses

-97

160

-335

-1,140

275

106

-329

-3,356

2,020

1,053

-320

-676

174

112

963

-808

-336

-811

507

2,076

1,250

-1,891

1,761

-3,637

359

1,771

-131

Value-added tax payable

-0

-1

-6

-

-27

-35

-71

-

-538

400

-243

432

-541

94

104

-175

75

-31

-170

175

305

-685

-67

35

-245

206

-672

Income tax recoverable

-

-

0

-

-

-

-58

-

-

-

-

435

-37

-435

343

-213

5

129

-21

-363

442

-931

-1,065

-1,891

1,601

814

-1,053

Exchange difference

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10

1

-0

56

121

82

9

Net cash provided by operating activities

-1

4,265

321

4,001

557

10

342

6,084

-646

-2,395

2,835

3,855

-1,581

-2,067

3,104

-4,798

3,520

4,007

6,179

1,453

-7,760

-3,023

5,746

-3,074

6,921

3,538

1,388

CASH FLOWS USED IN INVESTING ACTIVITIES
Payment for acquisition of Shaanxi Weinan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

0

822

-

-

-

-

Deposit paid for intended acquisition

-

-

-

-

-

-

-

6,499

-12

6

1,629

4,881

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deposit paid to intended acquisition

-

-

-

-

-

-

-

28

-0

0

30

2,384

4

477

1

3

23

950

4

0

18

13

0

5

5

15

84

Net cash used in investing activities

-44

-4,363

0

-6,378

0

0

0

-5,723

12

-6

-1,660

-9,957

-6

1,087

-1

-658

-2,886

-660

-4

-18,215

1,209

540

-822

-4,042

-3,124

912

-84

CASH FLOWS USED IN FINANCING ACTIVITIES
Repayment to a related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

669

-135

-199

Proceeds from short-term bank loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

9

315

458

Repayment of short-term bank loans

0

0

0

-2

-1

0

282

-25

-1

25

162

-

-

-3,257

0

-

-

-

-

-

-

-

-

-

-

-

-

Advance from a related party

-

-

-

-

-

-

-

-

-

-

-

-

36

-73

107

-

-

-

-

-

-

-

-

-

-

-

-

Advance from (repayment to) a related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6

-9

-1,592

-

-

-

-

-

-

-

-

Proceeds from stock issuance and warrants

-

-

-

-

-

-

-

-

-

-

-

0

0

0

3,862

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from stock issuance and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Net cash used in financing activities

0

0

0

1,692

1

-0

-282

25

1

-25

-162

-232

33

3,183

3,970

-4,849

-6

-9

-1,592

6,336

0

-791

0

4

-325

450

657

Effect of exchange rate changes on cash and cash equivalents

3

21

-10

198

-107

104

-7

-459

430

30

12

221

12

4

-20

-164

-27

156

115

65

-38

13

74

77

157

179

124

Net increase in cash and cash equivalents

-42

-76

310

-486

452

115

52

-73

-201

-2,396

1,024

-6,114

-1,541

2,208

7,052

-10,471

600

3,494

4,698

-10,360

-6,590

-3,260

4,998

-7,035

3,628

5,081

2,085

SUPPLEMENTAL DISCLOSURES:
Interest received

0

0

1

1

0

0

0

3

-0

0

4

660

669

-1

1

-

-

-

6

296

0

0

0

-

-

-

-

Interest paid

0

0

0

-105

105

38

0

74

-0

-1

61

71

82

0

0

166

378

-282

93

-62

0

0

0

-

-

-

-

Income tax payments

-

-

-

-

-

-

-

-

-

-

-

0

138

434

92

307

1,217

-748

188

-38

-105

-3,903

1,660

-3,501

-21

-5,276

2,099